Table 1.
Patient demographic and clinical characteristics (ITT population).
| Characteristics | Total N = 150 |
|---|---|
| Age: median (min, max), years old | 58 (25–76) |
| Sex, n (%) | |
| Male | 111 (74.0) |
| Smoking status, n (%) | |
| Smoker | 94 (62.7) |
| Histology, n (%) | |
| Adenocarcinoma | 99 (66.0) |
| Squamous cell carcinoma | 35 (23.3) |
| Others | 16 (10.7) |
| Clinical stage, n (%) | |
| IIIB | 6 (4.0) |
| IV | 144 (96.0) |
| Driver mutations, n (%) | |
| EGFR a | 23 (15.3) |
| ALK | 6 (4.0) |
| Wild type | 102 (68.0) |
| Unknown | 19 (12.7) |
| Chemotherapy, n (%) | |
| Gemcitabine plus platinum | 95 (63.3) |
| Pemetrexed plus platinum | 40 (26.7) |
| Paclitaxol plus platinum b | 14 (9.3) |
| Pemetrexed | 1 (0.7) |
a
EGFR driver mutation: exon 19 deletion in 7, exon 20 insertion in 6, L858R in 3, L861Q in 2, and uncommon mutation in 5.
b
Including three cases of polymeric micelle-formulated paclitaxel (Genexol-PM) plus cisplatin.
ALK, anaplastic lymphoma kinase; CTC, circulating tumor cells; EGFR, epidermal growth factor receptor; ITT, intention to treat.